GGCX and prostate neoplasm: Prediction based on colocalization analysis suggests that inhibition of GGCX may lower CAD-risk, but according to the PheWAS it is associated with an increase risk of malignant neoplasm of prostate (PPheWAS = 3.06 × 10–9) (Additional file 15: Table S15).